Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation

International Journal of Surgical Oncology

Volumn 2013, Issue , 2013, Pages

  Li, Jianyi ^a   Zhang, Yang ^a   Zhang, Wenhai ^a   Jia, Shi ^a   Tian, Rui ^a   Kang, Ye ^a   Ma, Yan ^a   Li, Dan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN21 MICRORNA, HUMAN; TIMP3 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER;

ADULT; ARTICLE; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETICS; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; SECONDARY;

ADULT; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR MARKERS, BIOLOGICAL;

EID: 84880908107     PISSN: 20901402     EISSN: 20901410     Source Type: Journal    
DOI: 10.1155/2013/875078     Document Type: Article

References (22)

1. Desantis C., Siegel R., Bandi P., Jemal A., Breast cancer statistics, 2011. CA Cancer Journal for Clinicians 2011 61 6 409 418 2-s2.0-81355164576 10.3322/caac.20134
2. Turaga K., Acs G., Laronga C., Gene expression profiling in breast cancer. Cancer Control 2010 17 3 177 182 2-s2.0-77955007882
3. Figueira R. C. S., Gomes L. R., Neto J. S., Silva F. C., Silva I. D. C. G., Sogayar M. C., Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009 9 article 20 2-s2.0-59249086792 10.1186/1471-2407-9- 20
4. Wang Z.-D., Huang C., Li Z.-F., Yang J., Li B.-H., Liang R.-R., Dai Z.-J., Liu Z.-W., Chrysanthemum indicum ethanolic extract inhibits invasion of hepatocellular carcinoma via regulation of MMP/TIMP balance as therapeutic target. Oncology Reports 2010 23 2 413 421 2-s2.0-76649142108 10.3892/or-00000650
5. Bourboulia D., Stetler-Stevenson W. G., Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Seminars in Cancer Biology 2010 20 3 161 168 2-s2.0-77956301181 10.1016/j.semcancer.2010.05.002
6. Munker R., Calin G. A., MicroRNA profiling in cancer. Clinical Science 2011 121 4 141 158 2-s2.0-79956190689 10.1042/CS20110005
7. Yang C. H., Yue J., Pfeffer S. R., Handorf C. R., Pfeffer L. M., MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. Journal of Biological Chemistry 2011 286 45 39172 39178 2-s2.0-80655125015 10.1074/jbc.M111.285098
8. Song B., Wang C., Liu J., Wang X., Lv L., Wei L., Xie L., Zheng Y., Song X., MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. Journal of Experimental and Clinical Cancer Research 2010 29 1, article 29 2-s2.0-77950905590 10.1186/1756-9966-29-29
9. Garbe C., Eigentler T. K., Bauer J., Blödorn-Schlicht N., Fend F., Hantschke M., Kurschat P., Kutzner H., Metze D., Preßler H., Reusch M., Röcken M., Stadler R., Tronnier M., Yazdi A., Metzler G., Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations for general practice. Journal of the German Society of Dermatology 2011 9 9 690 699 2-s2.0-80052498194 10.1111/j.1610-0387.2011.07714.x
10. Heimann R., Hellman S., Aging, progression, and phenotype in breast cancer. Journal of Clinical Oncology 1998 16 8 2686 2692 2-s2.0-0031904275 (Pubitemid 28363031)
11. Aresu L., Benali S., Garbisa S., Gallo E., Castagnaro M., Matrix metalloproteinases and their role in the renal epithelial mesenchymal transition. Histology and Histopathology 2011 26 3 307 313 2-s2.0-79952350073
12. Wang Y., Zhou B. P., Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chinese Journal of Cancer 2011 30 9 603 611 2-s2.0-80053074082 10.5732/cjc.011.10226
13. Dirier A., Burhanedtin-Zincircioglu S., Karadayi B., Isikdogan A., Aksu R., Characteristics and prognosis of breast cancer in younger women. Journal of B.U.ON 2009 14 4 619 623 2-s2.0-75149132875
14. Von Tempelhoff G.-F., Schönmann N., Heilmann L., Thrombosis-a clue of poor prognosis in primary non-metastatic breast cancer? Breast Cancer Research and Treatment 2002 73 3 275 277 2-s2.0-0035992551 10.1023/A: 1015864322007 (Pubitemid 34713001)
15. Lee J. S., Kim S. I., Choi S. Y., Park H. S., Lee J. S., Park S., Koo J., Park B.-W., Lee K. S., Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes. International Journal of Clinical Oncology 2011 16 5 473 481 2-s2.0-84857096695
16. Millar E. K. A., Graham P. H., McNeil C. M., Browne L., O'Toole S. A., Boulghourjian A., Kearsley J. H., Papadatos G., Delaney G., Fox C., Nasser E., Capp A., Sutherland R. L., Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. British Journal of Cancer 2011 105 2 272 280 2-s2.0-79960221711 10.1038/bjc.2011.228
17. Qian B., Katsaros D., Lu L., Preti M., Durando A., Arisio R., Mu L., Yu H., High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF- β 1. Breast Cancer Research and Treatment 2009 117 1 131 140 2-s2.0-69049120925 10.1007/s10549-008-0219-7
18. Calin G. A., Sevignani C., Dumitru C. D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., Bullrich F., Negrini M., Croce C. M., Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America 2004 101 9 2999 3004 2-s2.0-12144290519 10.1073/pnas.0307323101 (Pubitemid 38327724)
19. Calin G. A., Croce C. M., Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. Journal of Clinical Investigation 2007 117 8 2059 2066 2-s2.0-34547702505 10.1172/JCI32577 (Pubitemid 47219545)
20. Gabriely G., Wurdinger T., Kesari S., Esau C. C., Burchard J., Linsley P. S., Krichevsky A. M., MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Molecular and Cellular Biology 2008 28 17 5369 5380 2-s2.0-50249173450 10.1128/MCB.00479-08
21. Selaru F. M., Olaru A. V., Kan T., David S., Cheng Y., Mori Y., Yang J., Paun B., Jin Z., Agarwal R., Hamilton J. P., Abraham J., Georgiades C., Alvarez H., Vivekanandan P., Yu W., Maitra A., Torbenson M., Thuluvath P. J., Gores G. J., LaRusso N. F., Hruban R., Meltzer S. J., MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009 49 5 1595 1601 2-s2.0-66149110971 10.1002/hep.22838
22. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A. E., Hoon D. S. B., Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clinical Chemistry 2011 57 1 84 91 2-s2.0-78650977713 10.1373/clinchem.2010.151845